VeriSign (NASDAQ:VRSN – Get Free Report) and Portage Biotech (NASDAQ:ALP – Get Free Report) are both technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.
Volatility & Risk
VeriSign has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
Earnings & Valuation
This table compares VeriSign and Portage Biotech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VeriSign | $1.66 billion | 16.62 | $825.70 million | $9.30 | 33.00 |
| Portage Biotech | $100,000.00 | 32.55 | -$38.63 million | ($409.00) | -0.01 |
VeriSign has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than VeriSign, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for VeriSign and Portage Biotech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VeriSign | 0 | 2 | 4 | 0 | 2.67 |
| Portage Biotech | 1 | 2 | 0 | 0 | 1.67 |
VeriSign currently has a consensus target price of $352.00, indicating a potential upside of 14.71%. Portage Biotech has a consensus target price of $12.50, indicating a potential upside of 495.24%. Given Portage Biotech’s higher possible upside, analysts plainly believe Portage Biotech is more favorable than VeriSign.
Institutional & Insider Ownership
92.9% of VeriSign shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 0.6% of VeriSign shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares VeriSign and Portage Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VeriSign | 49.06% | -38.40% | 59.95% |
| Portage Biotech | N/A | N/A | N/A |
Summary
VeriSign beats Portage Biotech on 10 of the 13 factors compared between the two stocks.
About VeriSign
VeriSign, Inc. operates critical internet infrastructure, best known for managing the domain-name registries for .com and .net. It provides the systems that allow domain names in these extensions to be registered and resolved through the Domain Name System, working with registrars that serve businesses and individuals. The company also provides registry services for other domain extensions and supports the security and stability of the internet’s naming infrastructure. Its services are used globally through a network of registrars and other internet service providers.
About Portage Biotech
Portage Biotech was a clinical-stage biotechnology company focused on developing immuno-oncology treatments for cancer. Its research centered on therapies intended to help the immune system recognize and attack tumors. The company’s pipeline included programs targeting invariant natural killer T cells and other immune pathways, including mechanisms within the tumor microenvironment. Its work was aimed at developing treatments that could be used alone or alongside other cancer therapies. Portage Biotech operated as a development-stage company, with its programs primarily in research and clinical development rather than commercial sales.
Receive News & Ratings for VeriSign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VeriSign and related companies with MarketBeat.com's FREE daily email newsletter.
